ARAVA Drug Patent Profile

Which patents cover Arava, and what generic alternatives are available?

Arava is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in ARAVA is leflunomide. There are seven drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leflunomide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Arava

A generic version of ARAVA was approved as leflunomide by APOTEX on September 13^th, 2005.

Summary for ARAVA

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ARAVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-001	Sep 10, 1998	AB	RX	Yes	No
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-002	Sep 10, 1998	AB	RX	Yes	Yes
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-003	Sep 10, 1998		RX	Yes	Yes

International Patents for ARAVA

See the table below for patents covering ARAVA around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	486750
Japan	2514190
Greece	72731
Luxembourg	90466
Egypt	13926	AN ISOXAZOLE DERIVATIVES PROCESSES FOR ITS PREPARATION COMPOSITIONS CONTAINING IT AND ITS USE FOR COMBATING RHEUMATISM

Investment Scenario and Fundamentals Analysis for ARAVA (Leflunomide)

Last updated: February 3, 2026

Overview of ARAVA

ARAVA (Leflunomide) is an oral disease-modifying anti-rheumatic drug (DMARD) approved for the treatment of rheumatoid arthritis (RA). It inhibits pyrimidine synthesis, suppressing immune response and reducing inflammation. Approved by the FDA in 1998, its primary indication is for adult patients with active RA.

Market Landscape and Commercial Potential

Market Size and Growth

The global rheumatoid arthritis market was valued at approximately $27 billion in 2021 and is projected to reach $35 billion by 2027, growing at a compound annual growth rate (CAGR) of roughly 4.3%. Key drivers include increasing prevalence, enhanced diagnosis rates, and demand for effective oral therapies.

ARAVA’s Market Position

ARAVA holds a niche in the RA treatment space alongside competitors like methotrexate, hydroxychloroquine, and biologic agents (e.g., adalimumab, etanercept). Its main advantages are oral administration and a well-characterized safety profile. Its market share remains around 3-5% among DMARDs.

Competitive Dynamics

• Patents and Exclusivity: Patent rights expired in most markets, with some jurisdictions offering data exclusivity or secondary patents extending its commercial life. Generic versions are available, lowering revenues.
• Emerging Alternatives: Biologics and biosimilars are gaining ground, offering higher efficacy but at increased cost and injection routes.
• Pricing: The drug’s price has declined due to generic competition, with U.S. retail prices around $2,500-$3,500 per month.

Regulatory and Patent Status

• Patent Expiry: Primary patents expired in the U.S. in 2018, with some secondary patents potentially extending exclusivity until 2023-2025.
• Regulatory Approvals: Approved for RA in multiple regions, including the U.S., EU, and Japan.

Clinical and Safety Profile

Evidence Base

• Extensive clinical trials demonstrate efficacy in reducing RA symptoms and slowing radiographic progression.
• Well-characterized safety profile with risks of hepatotoxicity, hematological effects, and teratogenicity. Proper monitoring mitigates adverse events.

New Indications

Efforts to expand ARAVA's use in other autoimmune diseases, such as psoriatic arthritis, have not led to widespread approval, constraining growth.

Investment Fundamentals

Revenue and Profitability

• Estimated global sales: approximately $200 million in 2022, dominated by generic market segments.
• Margins are compressed in generic markets; branded sales margins are higher but declining.
• Patent expiries have led to price erosion.

R&D and Pipeline

• No current approvals for new indications.
• Limited R&D activity due to market mature status.
• Potential for lifecycle management through combination therapies or novel formulation to extend commercial viability.

Market Risks

• Generic Competition: Generics significantly reduce prices and market share.
• Biologics Competition: Shift towards biologics and biosimilars diminishes the relevance of oral DMARDs.
• Regulatory and Pricing Pressures: Healthcare systems are reducing drug prices through negotiations and increased use of biosimilars.

Investment Outlook

ARAVA's core market is declining, with revenues expected to continue falling unless new formulations or indications are developed. Potential investor interest could stem from lifecycle extension strategies or niche indications, but current fundamentals suggest limited growth prospects.

Financial and Strategic Considerations

Aspect	Status	Implication
Patent Protection	Expired (U.S. in 2018)	Revenue decline expected
Generic Competition	Strong	Price erosion, volume growth limited
Market Share	Stable but declining	Future growth unlikely without innovation
R&D Pipeline	Limited	No near-term catalysts
Pricing Trends	Downward pressure	Margins shrinking

Key Challenges

• Diminishing exclusivity
• Competition from biosimilars
• Evolving treatment landscape favoring biologics
• Pricing pressure on mature products

Summary

ARAVA faces a contracting market with declining revenues driven by patent expiry, generic inflow, and competition from biologics. The drug maintains limited competitive advantages, mainly its oral administration route, but these are increasingly overshadowed by newer therapies. Investment prospects are constrained unless strategies involve pipeline expansion or lifecycle management.

Key Takeaways

• ARAVA’s sales peaked pre-2018; current revenues are in decline.
• Patent expirations and generic entries erode profitability.
• Biologics and biosimilars pose significant competition. -，没有具体新 indications或 formulations，增长空间有限。
• Strategic value depends on lifecycle extension or pipeline innovations.

Frequently Asked Questions

1. What is the primary market for ARAVA?
The primary market is rheumatoid arthritis treatment, with a focus on adult patients who prefer oral medications.

2. How does ARAVA compare to biologic therapies?
ARAVA is less effective than biologics in some cases but offers an oral administration route and lower cost, making it suitable for certain patient segments.

3. What are the main patent challenges facing ARAVA?
Most key patents have expired, with generic competition intensifying and reducing revenue margins.

4. Are there efforts to repurpose or extend ARAVA’s indications?
Limited activity has been observed; no approved new indications currently exist.

5. What future strategies could sustain ARAVA’s value?
Lifecycle management, such as reformulations or combination therapies, might provide limited extension. However, no major initiatives are publicly underway.

Citations

1. Market data: Global Rheumatoid Arthritis Market Size, Trends & Forecasts, 2021-2027.
2. Patent and regulatory information: FDA, European Patent Office filings, 2022.
3. Clinical profile: Rheumatology Journals; ARAVA prescribing information.